Alector's low P/S ratio may be due to poor revenue performance and expectations of this trend continuing. Future revenue growth is expected to be significantly lower than the industry, possibly causing discomfort among shareholders and a drop in share price.
Arnon Rosenthal's major sale indicates insiders may expect a lower price. Despite high insider ownership, the absence of insider purchases and significant sales stirs uncertainty about the company's prospects and arouses investor caution.
Gapping up $衛訊公司(VSAT.US)$+5.9% (the Wall Street Journal reported that the satellite company was close to a deal to sell a military communications unit to defense contractor$L3Harris Technologies(LHX.US)$for nearly $2 billion.) $Myovant Sciences(MYOV.US)$+31.3% (the biopharmaceutical company rejected a bid by its largest shareholder, Sumitovant Biopharma, to buy the shares it doesn’t already own for $22.75 per share. Myovant said...
Gainers: •$Antares Pharma(ATRS.US)$+48.7% (to be acquired by Halozyme (HALO) for $5.60 per share) •$Sierra Oncology(SRRA.US)$+37.9% (acquired by GSK for $55 per share) •$Amryt Pharma(AMYT.US)$+11.7% (announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL open label extension study in acromegaly patients) •$BriaCell Therapeutics(BCTX.US)$+6% (presents development details of...
Alector股票討論區
$Alector(ALEC.US)$
$PacWest Bancorp(PACW.US)$
Who will squeeze best?
All in or just a little?
$衛訊公司(VSAT.US)$ +5.9% (the Wall Street Journal reported that the satellite company was close to a deal to sell a military communications unit to defense contractor $L3Harris Technologies(LHX.US)$ for nearly $2 billion.)
$Myovant Sciences(MYOV.US)$ +31.3% (the biopharmaceutical company rejected a bid by its largest shareholder, Sumitovant Biopharma, to buy the shares it doesn’t already own for $22.75 per share. Myovant said...
• $Antares Pharma(ATRS.US)$ +48.7% (to be acquired by Halozyme (HALO) for $5.60 per share)
• $Sierra Oncology(SRRA.US)$ +37.9% (acquired by GSK for $55 per share)
• $Amryt Pharma(AMYT.US)$ +11.7% (announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL open label extension study in acromegaly patients)
• $BriaCell Therapeutics(BCTX.US)$ +6% (presents development details of...
• $博思艾倫諮詢公司(BAH.US)$: Goldman Sachs Upgrades to Buy from Neutral - PT $102 (from $83)
• $哈門那(HUM.US)$: UBS Upgrades to Buy from Neutral - PT $520 (from $486)
• $JB亨特運輸服務(JBHT.US)$: Deutsche Bank Upgrades to Buy from Hold - PT $230 (from $210)
Downgrades
• $JB亨特運輸服務(JBHT.US)$: B.Riley Downgrades to Neutral from Buy - PT $33 (from $62)
• $CACI國際(CACI.US)$: Goldman Sachs Downgrad...
暫無評論